Therapy Areas: Devices
BrainCheck secures USD10m in Series B Funding
3 November 2021 -

Cognitive healthcare platform BrainCheck disclosed on Wednesday that it has secured USD10m in a Series B funding round led by Next Coast Ventures and S3 Ventures.

Additional investors include Nueterra Capital, Tensility Ventures and True Wealth Ventures.

Also, UPMC Enterprises and SelectQuote (NYSE: SLQT) have joined as strategic investors.

BrainCheck said this funding round takes the total capital raised by the company to USD20m.

The BrainCheck platform is FDA Class II Software as a Medical Device (SaMD), which allows physicians to facilitate in-person or remote assessment for early and accurate impressions of cognitive function. Designed to reduce the human and economic toll of cognitive impairment and dementia, it is used in over 400 neurology, primary care and geriatrics practices, as well as being leveraged by researchers and clinicians studying and treating the long-term cognitive issues from COVID-19.

Yael Katz, PhD, co-founder and CEO of BrainCheck, stated: "With early diagnosis comes treatment and intervention. These funds will allow us to accelerate the adoption of our platform and work with clinicians to help more patients live better and safer lives, decrease caregiver frustration, and save health systems trillions of dollars. I believe that BrainCheck can help cognitive care evolve the way cancer care has since the 1970s, when chemotherapy was one-size-fits-all."